Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity in patients with chronic kidney disease (CKD), raising the hope of more effective treatments.
At the American Society of Nephrology (ASN) Kidney Week 2023 congress, AstraZeneca and Boehringer Ingelheim both presented data from mid-stage trials of combinations that will now be taken forward into phase 3 programmes.
